Comparison · NCT03675308-sae
Risankizumab vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Risankizumab vs Placebo: serious adverse events. Trial comparisons, record NCT03675308-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03675308-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0248 | 0.0143 | 0.0429 | wilson | |
| Risk in group 2 | 0.0374 | 0.0238 | 0.0584 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0126 | -0.036 | 0.0101 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.664 | 0.323 | 1.36 | log | |
| Odds ratio, group 1 over group 2 | 0.655 | 0.312 | 1.38 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Risankizumab than on Placebo | 79.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Risankizumab | Participants received 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. | 12 | 483 | EG001 |
| Group 2 | Placebo | Participants received placebo administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. | 18 | 481 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose of study drug to Week 24
Source ClinicalTrials.gov
Trial
- Title
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
- NCT number
- NCT03675308
- Phases
- PHASE3
- Conditions
- Psoriatic Arthritis
- Interventions
- Placebo, Risankizumab
- Lead sponsor
- AbbVie
- Results first posted
- 2022-02-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03675308?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03675308-sae